When a person suffers a stroke, every moment counts. Doctors are always looking for ways to help patients regain their independence and mobility after the initial emergency. A recent trial involving 235 patients in China looked at a treatment called fibrinogenase to see if it could improve outcomes for those who had not received other reperfusion therapies.
The study found that patients who received the fibrinogenase injection had significantly better functional outcomes after 90 days compared to those who received a placebo. These patients also showed lower scores on the NIHSS, which is a scale used to measure the severity of stroke symptoms. The results were particularly strong for people treated within 48 hours of their symptoms starting, as well as those with mild to moderate strokes caused by specific types of artery blockages.
Safety data showed that the risk of bleeding or death during treatment was similar between the two groups. While these results are promising, the researchers noted that the overall evidence for the treatment's effects is still limited. Because the data is still emerging, patients should talk to their doctors about how these findings might apply to specific cases.
